Skip to content
OpenCapital
Get started

Pfizer PFE Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

Amgen logo
AmgenAMGN
——

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Pfizer (PFE) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $3M in Q1 2026.
How has Pfizer's debt instrument, unamortized discount (premium) and debt issuance costs, net changed year-over-year?
Pfizer's debt instrument, unamortized discount (premium) and debt issuance costs, net increased by 200.0% year-over-year, from $1M to $3M.
What is the long-term trend for Pfizer's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Over 3 years (2020 to 2025), Pfizer's debt instrument, unamortized discount (premium) and debt issuance costs, net has grown at a 14.5% compound annual growth rate (CAGR), from $2M to $3M.